MA vs PFE: Which Is the Better Buy?
Side-by-side comparison of Mastercard Incorporated and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-17.
Mastercard Incorporated · Financial Services
$543.60
+45.0% upside to fair value
High Conviction
Grade A
High Quality
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
MA has more upside to fair value
(+45.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MA |
PFE |
| Current Price |
$543.60 |
$25.22 |
| Fair Value Estimate |
$788.22 |
$25.92 |
| Upside to Fair Value |
+45.0%
|
+2.8%
|
| Market Cap |
$480.3B |
$143.7B |
| Forward P/E |
—
|
19.2x
|
| EV / EBITDA |
23.3x
|
12.3x
|
| Price / Sales |
14.2x
|
2.3x
|
| Price / FCF |
27.1x
|
15.2x
|
| Revenue Growth YoY |
+15.8%
|
+5.4%
|
| Gross Margin |
83.0%
|
69.3%
|
| Operating Margin |
59.4%
|
23.4%
|
| Return on Equity |
206.1%
|
8.4%
|
| Dividend Yield |
0.62% |
0% |
| FCF Yield |
3.69%
|
6.6%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Mastercard operates a global two-sided payments network that connects issuers, acquirers, merchants and cardholders, monetizing payment volumes and an expanding set of security, data, authentication and other value-added services. Business quality is high: the network benefits from powerful acceptance and scale effects, 83.0% gross margin, 59.4% operating margin, 45.9% net margin, 206.1% ROE, and…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
MA |
PFE |
| Zone Low |
$591.16 |
$19.44 |
| Zone High |
$669.99 |
$22.03 |
| In Buy Zone? |
Yes
|
No
|